InvestSMART

BCAL Diagnostics Limited (ASX:BDX)

ALERT: Price-sensitive ASX Announcement for BDX
Current share price for BDX : $0.082 0.024 (41.38%)+
Release
21 Aug 2026 6:14PM
Price at Release
$0.058
Full Release
download
Summary
BCAL Diagnostics Limited announced securing a $10 million Convertible Note Facility to fund its operations for the financial year 2027. This facility was approved by shareholders during the Annual General Meeting held in 2025. The terms include the conversion of notes into shares at a discount to the 28-day Volume Weighted Average Price (VWAP), with a minimum conversion price of $0.096459. The notes carry an interest of 10% per annum, which is capitalized annually. The facility is designed to support the company's product commercialization and enhance working capital, with notes being issued to professional and sophisticated investors.
Key Points
  • BCAL Diagnostics Limited secures $10 million Convertible Note Facility for FY2027.
  • Shareholders approved the facility at the 2025 AGM.
  • The facility allows for conversion of notes into shares at a discount to the 28-day VWAP.
  • Minimum conversion price set at $0.096459.
  • Interest on the notes is 10% per annum, capitalized annually.
  • Convertible notes to be issued to professional and sophisticated investors.
  • The facility supports product commercialization and working capital.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.